Abstract
Two non-pathogenic scaffolds (represented by the filamentous bacteriophage fd and the dihydrolipoyl acetyltransferase E2 protein of the Bacillus stearothermophilus pyruvate dehydrogenase (PDH) complex) able to deliver human immunodeficiency virus (HIV)-1 antigenic determinants, were designed in our laboratories and investigated in controlled assay conditions. Based on a modification of the phage display technology, we developed an innovative concept for a safe and inexpensive vaccine in which conserved antigenic determinants of HIV-1 reverse transcriptase (RTase) were inserted into the N-terminal region of the major pVIII coat protein of bacteriophage fd virions. Analogously, we developed another antigen delivery system based on the E2 component from the PDH complex and capable of displaying large intact proteins on the surface of an icosahedral lattice. Our data show that both of these systems can deliver B and T epitopes to their respective presentation compartments in target cells and trigger a humoral response as well as a potent helper and cytolytic response in vitro and in vivo.
Keywords: vaccine, filamentous bacteriophage fd, phage display, dihydrolipoyl acetyltransferase
Current HIV Research
Title: Use of Fusion Proteins and Procaryotic Display Systems for Delivery of HIV-1 Antigens: Development of Novel Vaccines for HIV-1 Infection
Volume: 1 Issue: 4
Author(s): Piergiuseppe De Berardinis, Rossella Sartorius, Antonella Caivano, Dina Mascolo, Gonzalo J. Domingo, Giovanna Del Pozzo, Muriel Gaubin, Richard N. Perham, Dominique Piatier-Tonneau and John Guardiola
Affiliation:
Keywords: vaccine, filamentous bacteriophage fd, phage display, dihydrolipoyl acetyltransferase
Abstract: Two non-pathogenic scaffolds (represented by the filamentous bacteriophage fd and the dihydrolipoyl acetyltransferase E2 protein of the Bacillus stearothermophilus pyruvate dehydrogenase (PDH) complex) able to deliver human immunodeficiency virus (HIV)-1 antigenic determinants, were designed in our laboratories and investigated in controlled assay conditions. Based on a modification of the phage display technology, we developed an innovative concept for a safe and inexpensive vaccine in which conserved antigenic determinants of HIV-1 reverse transcriptase (RTase) were inserted into the N-terminal region of the major pVIII coat protein of bacteriophage fd virions. Analogously, we developed another antigen delivery system based on the E2 component from the PDH complex and capable of displaying large intact proteins on the surface of an icosahedral lattice. Our data show that both of these systems can deliver B and T epitopes to their respective presentation compartments in target cells and trigger a humoral response as well as a potent helper and cytolytic response in vitro and in vivo.
Export Options
About this article
Cite this article as:
Berardinis De Piergiuseppe, Sartorius Rossella, Caivano Antonella, Mascolo Dina, Domingo J. Gonzalo, Pozzo Del Giovanna, Gaubin Muriel, Perham N. Richard, Piatier-Tonneau Dominique and Guardiola John, Use of Fusion Proteins and Procaryotic Display Systems for Delivery of HIV-1 Antigens: Development of Novel Vaccines for HIV-1 Infection, Current HIV Research 2003; 1 (4) . https://dx.doi.org/10.2174/1570162033485168
DOI https://dx.doi.org/10.2174/1570162033485168 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulatory Triangle of Neurodegeneration, Adult Neurogenesis and MicroRNAs
CNS & Neurological Disorders - Drug Targets Silkworm as a Host of Baculovirus Expression
Current Pharmaceutical Biotechnology Structure-Function Relationships of Phytochemicals in Control of Mosquito Vectors
Current Organic Chemistry The Recent Progress in RSV Vaccine Technology
Recent Patents on Anti-Infective Drug Discovery Recent Developments in Delivery of Nucleic Acid-Based Antiviral Agents
Current Pharmaceutical Design Current Approaches in Antiviral Drug Discovery Against the Flaviviridae Family
Current Pharmaceutical Design Role of CD14 in Host Response to Infection
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Initiation of the Immune Response by Extracellular Hsp72: Chaperokine Activity of Hsp72
Current Immunology Reviews (Discontinued) An Overview of Acute Flaccid Myelitis
CNS & Neurological Disorders - Drug Targets EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research The Immune System of Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pseudotyping Viral Vectors With Emerging Virus Envelope Proteins
Current Gene Therapy Animal Models of Systemic Sclerosis
Current Pharmaceutical Design Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology Recent Patents on Nucleic Acid-Based Antiviral Therapeutics
Recent Patents on Anti-Infective Drug Discovery Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging Regulatory T Cells and Allergic Disease
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Water in the Brain: Role of Aquaporin-4 in Ischemic Brain Edema
Current Drug Targets A Systems Biology Perspective on Rational Design of Peptide Vaccine Against Virus Infections
Current Topics in Medicinal Chemistry AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued)